Annual SGA
$5.23 M
-$1.47 M-21.92%
December 31, 2023
Summary
- As of February 8, 2025, ENLV annual SGA is $5.23 million, with the most recent change of -$1.47 million (-21.92%) on December 31, 2023.
- During the last 3 years, ENLV annual SGA has risen by +$1.63 million (+45.28%).
- ENLV annual SGA is now -25.08% below its all-time high of $6.99 million, reached on December 31, 2016.
Performance
ENLV SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$771.00 K
-$216.00 K-21.88%
September 30, 2024
Summary
- As of February 8, 2025, ENLV quarterly SGA is $771.00 thousand, with the most recent change of -$216.00 thousand (-21.88%) on September 30, 2024.
- Over the past year, ENLV quarterly SGA has dropped by -$508.00 thousand (-39.72%).
- ENLV quarterly SGA is now -70.73% below its all-time high of $2.63 million, reached on March 31, 2016.
Performance
ENLV Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$469.59 M
-$18.93 M-4.20%
September 30, 2024
Summary
- As of February 8, 2025, ENLV TTM SGA is -$469.59 million, with the most recent change of -$18.93 million (-4.20%) on September 30, 2024.
- Over the past year, ENLV TTM SGA has dropped by -$475.83 million (-7621.80%).
- ENLV TTM SGA is now -33441.86% below its all-time high of -$1.40 million.
Performance
ENLV TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
ENLV Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.9% | -39.7% | -7621.8% |
| 3 y3 years | +45.3% | -52.0% | -7229.0% |
| 5 y5 years | +339.8% | -52.0% | -7229.0% |
ENLV Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -21.9% | at low | -68.9% | +5.2% | -155.6% | at low |
| 5 y | 5-year | -21.9% | +82.3% | -68.9% | +21.8% | -434.5% | at low |
| alltime | all time | -25.1% | +5984.9% | -70.7% | +130.8% | <-9999.0% | at low |
Enlivex Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $771.00 K(-21.9%) | $3.58 M(-12.4%) |
| Jun 2024 | - | $987.00 K(-9.7%) | $4.09 M(-13.3%) |
| Mar 2024 | - | $1.09 M(+49.1%) | $4.72 M(-9.8%) |
| Dec 2023 | $5.23 M(-21.9%) | $733.00 K(-42.7%) | $5.23 M(-16.2%) |
| Sep 2023 | - | $1.28 M(-20.8%) | $6.24 M(-3.1%) |
| Jun 2023 | - | $1.61 M(+0.4%) | $6.44 M(-2.2%) |
| Mar 2023 | - | $1.61 M(-7.8%) | $6.59 M(-1.7%) |
| Dec 2022 | $6.70 M(+7.4%) | $1.74 M(+18.1%) | $6.70 M(-9.9%) |
| Sep 2022 | - | $1.48 M(-16.2%) | $7.44 M(+4.1%) |
| Jun 2022 | - | $1.76 M(+2.3%) | $7.15 M(+7.4%) |
| Mar 2022 | - | $1.72 M(-30.6%) | $6.66 M(+6.7%) |
| Dec 2021 | $6.24 M(+73.2%) | $2.48 M(+109.4%) | $6.24 M(+27.0%) |
| Sep 2021 | - | $1.19 M(-6.6%) | $4.92 M(+7.6%) |
| Jun 2021 | - | $1.27 M(-2.8%) | $4.57 M(+6.9%) |
| Mar 2021 | - | $1.30 M(+12.9%) | $4.27 M(+18.7%) |
| Dec 2020 | $3.60 M(+25.5%) | $1.16 M(+38.1%) | $3.60 M(+6.4%) |
| Sep 2020 | - | $837.00 K(-14.2%) | $3.39 M(+9.4%) |
| Jun 2020 | - | $976.00 K(+54.2%) | $3.09 M(+13.8%) |
| Mar 2020 | - | $633.00 K(-32.7%) | $2.72 M(-5.3%) |
| Dec 2019 | $2.87 M(+141.2%) | $940.00 K(+72.5%) | $2.87 M(+13.9%) |
| Sep 2019 | - | $545.00 K(-9.3%) | $2.52 M(+16.1%) |
| Jun 2019 | - | $601.00 K(-23.3%) | $2.17 M(+24.1%) |
| Mar 2019 | - | $784.00 K(+32.9%) | $1.75 M(+47.1%) |
| Dec 2018 | $1.19 M | $590.00 K(+201.0%) | $1.19 M(-162.7%) |
| Sep 2018 | - | $196.00 K(+8.9%) | -$1.90 M(+31.8%) |
| Jun 2018 | - | $180.00 K(-19.6%) | -$1.44 M(+68.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $224.00 K(-109.0%) | -$853.00 K(-283.8%) |
| Dec 2017 | $464.00 K(-93.4%) | -$2.50 M(-482.1%) | $464.00 K(-89.1%) |
| Sep 2017 | - | $654.00 K(-14.8%) | $4.25 M(-12.9%) |
| Jun 2017 | - | $768.00 K(-50.2%) | $4.87 M(-17.3%) |
| Mar 2017 | - | $1.54 M(+20.1%) | $5.89 M(-15.6%) |
| Dec 2016 | $6.99 M(+0.5%) | $1.28 M(+0.2%) | $6.99 M(-10.7%) |
| Sep 2016 | - | $1.28 M(-28.3%) | $7.82 M(-7.0%) |
| Jun 2016 | - | $1.79 M(-32.2%) | $8.41 M(+2.3%) |
| Mar 2016 | - | $2.63 M(+24.4%) | $8.22 M(+18.2%) |
| Dec 2015 | $6.95 M(+163.5%) | $2.12 M(+13.0%) | $6.95 M(+16.2%) |
| Sep 2015 | - | $1.87 M(+17.4%) | $5.99 M(+19.5%) |
| Jun 2015 | - | $1.60 M(+16.8%) | $5.01 M(+31.7%) |
| Mar 2015 | - | $1.37 M(+18.8%) | $3.81 M(+44.2%) |
| Dec 2014 | $2.64 M(+534.4%) | $1.15 M(+27.9%) | $2.64 M(+51.3%) |
| Sep 2014 | - | $899.00 K(+129.9%) | $1.74 M(+93.8%) |
| Jun 2014 | - | $391.00 K(+96.5%) | $900.00 K(+51.3%) |
| Mar 2014 | - | $199.00 K(-22.0%) | $595.00 K(+50.3%) |
| Dec 2013 | $416.00 K(+383.7%) | $255.00 K(+363.6%) | $396.00 K(+180.9%) |
| Sep 2013 | - | $55.00 K(-36.0%) | $141.00 K(+64.0%) |
| Jun 2013 | - | $86.00 K | $86.00 K |
| Dec 2012 | $86.00 K(-92.1%) | - | - |
| Dec 2002 | $1.09 M(-38.1%) | - | - |
| Dec 2001 | $1.76 M(+30.5%) | - | - |
| Dec 2000 | $1.35 M(+192.3%) | - | - |
| Dec 1999 | $460.80 K(-41.0%) | - | - |
| Dec 1998 | $781.40 K(-43.6%) | - | - |
| Dec 1997 | $1.39 M | - | - |
FAQ
- What is Enlivex Therapeutics annual SGA?
- What is the all time high annual SGA for Enlivex Therapeutics?
- What is Enlivex Therapeutics annual SGA year-on-year change?
- What is Enlivex Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Enlivex Therapeutics?
- What is Enlivex Therapeutics quarterly SGA year-on-year change?
- What is Enlivex Therapeutics TTM SGA?
- What is the all time high TTM SGA for Enlivex Therapeutics?
- What is Enlivex Therapeutics TTM SGA year-on-year change?
What is Enlivex Therapeutics annual SGA?
The current annual SGA of ENLV is $5.23 M
What is the all time high annual SGA for Enlivex Therapeutics?
Enlivex Therapeutics all-time high annual SGA is $6.99 M
What is Enlivex Therapeutics annual SGA year-on-year change?
Over the past year, ENLV annual SGA has changed by -$1.47 M (-21.92%)
What is Enlivex Therapeutics quarterly SGA?
The current quarterly SGA of ENLV is $771.00 K
What is the all time high quarterly SGA for Enlivex Therapeutics?
Enlivex Therapeutics all-time high quarterly SGA is $2.63 M
What is Enlivex Therapeutics quarterly SGA year-on-year change?
Over the past year, ENLV quarterly SGA has changed by -$508.00 K (-39.72%)
What is Enlivex Therapeutics TTM SGA?
The current TTM SGA of ENLV is -$469.59 M
What is the all time high TTM SGA for Enlivex Therapeutics?
Enlivex Therapeutics all-time high TTM SGA is -$1.40 M
What is Enlivex Therapeutics TTM SGA year-on-year change?
Over the past year, ENLV TTM SGA has changed by -$475.83 M (-7621.80%)